An amoxicillin 875 mg tablet is a prescription oral product containing 875 mg of the single antibacterial ingredient amoxicillin per conventional tablet. U.S. product labeling documents film-coated 875 mg tablets from more than one product or labeler family, with different imprints, appearances and package identifiers. Those differences matter when confirming what a licensed pharmacy has prepared, but the strength printed in an online listing does not tell a patient whether the medicine is appropriate for an infection.
One distinction should be checked before comparing anything else: amoxicillin 875 mg is not the same finished product as amoxicillin/clavulanate 875 mg/125 mg. The second medicine contains clavulanate as an additional active ingredient and has a separate prescription and product identity. A search result or pharmacy interface may shorten the name to “875 mg,” so the full ingredient line, dosage form and prescription label are essential. A pharmacist or prescriber must resolve any proposed product change; matching the amoxicillin number alone is not enough.
This page is a strength-specific product and fulfillment guide, not treatment or dose-selection advice. It compares traceable 875 mg plain-amoxicillin tablets, explains what imprints and NDCs can establish, and shows how to verify a quoted or dispensed product at a U.S. pharmacy. The broader amoxicillin tablet catalog covers the dosage form across strengths, while this guide keeps the 875 mg ordering task in focus.
For this page, “875 mg” means the amount of amoxicillin in one conventional tablet containing a single active antibacterial ingredient. Published U.S. labels identify film-coated tablets at this strength, but their color, scoring, inactive ingredients and packaging vary. A meaningful pharmacy listing specifies the complete drug name, strength and dosage form rather than displaying “875 mg” alone.
Some labels identify the ingredient as amoxicillin trihydrate while expressing the strength as the equivalent amount of amoxicillin. This is a product-label convention, not an instruction to select a particular tablet count or course length. The clinician’s prescription controls how the finished product is to be used.
Conventional amoxicillin capsules are commonly labeled in 250 mg and 500 mg strengths, so an 875 mg result accompanied by a generic capsule photograph deserves clarification. The amoxicillin capsule catalog covers capsule-specific products. This page focuses on identifiable 875 mg tablets and the information needed to match one to a valid prescription.
Plain amoxicillin 875 mg contains only amoxicillin. An amoxicillin/clavulanate 875 mg/125 mg tablet contains 875 mg of amoxicillin plus a second active ingredient, clavulanate potassium. These are different prescription medicines, not alternative brand names for an otherwise identical tablet.
Prescription histories, refill notices and pharmacy search results can abbreviate product names. “Augmentin 875,” “amox-clav 875/125” and “amoxicillin clavulanate” identify the combination category rather than plain amoxicillin. The Augmentin 875/125 product guide covers that separate formulation. A pharmacist or prescriber must resolve any ambiguity; the shared 875 mg amoxicillin amount is not permission to substitute.
The distinction also applies when evaluating an earlier refill, a manufacturer change or a lower-priced online result. A conventional 875 mg tablet containing plain amoxicillin must not be classified as an Augmentin generic, and a combination tablet cannot be classified as plain amoxicillin merely because the first strength number matches.
The following three examples are drawn from published U.S. labeling for plain-amoxicillin 875 mg tablets. They document distinguishable imprints, appearances, labeling companies and package NDCs. An NDC identifies a listed product or package; it does not independently prove FDA approval, current inventory or a retail offer.
The Preferred Pharmaceuticals record describes a relabeled Sandoz GG-962 tablet. The Proficient Rx record concerns repackaging of an A/6|7 tablet associated with a Rising Pharma source listing. The USAntibiotics record describes an AMOXIL-imprinted tablet; that imprint alone does not establish that an original branded retail package is currently marketed. Repackager and source NDCs serve different identification roles.
The examples also show why source-product information matters. An imprint belongs to the tablet itself; a package NDC belongs to the listed distribution package. Relabeling or repackaging can change the package identifier without changing the visible imprint on the underlying tablet. This is a reason to check the labeler and the actual pharmacy record together.
Revision and listing dates refer to the cited product documentation, not the last time a pharmacy checked stock. The pharmacist should verify the actual product against the current label and prescription before relying on an imprint or package identifier.
| Documented tablet / labeler | Appearance and identifying marks | Example package identifier | Record context; important limitation |
|---|---|---|---|
| Preferred Pharmaceuticals (relabeled Sandoz), 875 mg | White to slightly yellowish oval, 21 mm; scored; GG-962 on one side and 875 on the other | NDC 68788-4152-2 — bottle of 20 | Preferred relabel record dated July 15, 2026; source product NDC family 0781-5061; local supply not confirmed. |
| Proficient Rx (repackaged Rising-source tablet), 875 mg | Pink capsule-shaped, 21 mm; A on one side, 6 and 7 separated by a score line on the other | NDC 63187-325-14 — bottle of 14 | Repackaged label revised June 2026; source NDC family 57237-029; does not demonstrate original-source package availability. |
| USAntibiotics, 875 mg AMOXIL-imprinted tablet | Pink capsule-shaped, film-coated; AMOXIL over 875; scored on reverse | NDC 81964-219-14 — bottle of 20 | Listed in USAntibiotics prescribing information revised May 2024; current individual-package listing or pharmacy stock not independently verified. |
The documented GG-962 and A/6|7 tablets illustrate why an 875 mg prescription may look different from a previous fill. Shape, coating color and imprint are characteristics of a particular finished product, not universal features of all amoxicillin 875 mg tablets. An unexpected appearance should be checked against the actual labeler and product record.
The AMOXIL imprint creates another possible misunderstanding: its presence on a tablet can reflect an authorized-generic labeling context and does not, by itself, establish that a currently marketed original branded package was dispensed. A pharmacy can identify the supplied product by its prescription record, manufacturer or labeler, NDC and imprint rather than relying on brand-like lettering.
A pill-search photograph can be useful for narrowing possibilities, but it may show another manufacturer, a discontinued package or an unrelated tablet with similar dimensions. The published description must be tied to the exact drug, strength, form and listed product. If those fields do not agree, pharmacist confirmation takes precedence over visual similarity.
Inactive ingredients also differ among finished products. The published GG-962 formulation lists ingredients including ethylcellulose, hypromellose, talc and titanium dioxide; the pink A/6|7 formulation lists ingredients including D&C Red No. 30 aluminum lake and polyethylene glycol. These are product-specific labeling examples, not ingredient lists for every white or pink tablet.
A patient with a documented sensitivity or concern about a coating or excipient should ask the pharmacist to examine the exact dispensed formulation. Neither tablet color nor an online product image establishes the inactive-ingredient profile or independently authenticates a physical tablet.
Several documented 875 mg tablets, including GG-962, A/6|7 and AMOXIL-imprinted examples, have score lines. Scoring can help identify a product but is not, by itself, an instruction to divide it or evidence that splitting creates an appropriate replacement for another prescribed strength.
Questions about breaking, crushing or swallowing a particular tablet should be addressed with the pharmacist or prescriber using the actual product label. The presence or absence of a score line is an identifying feature, not authorization to change the prescribed amount or administration directions.
For identification, the score should be considered together with the imprint and the tablet’s manufacturer-specific description. If a delivered tablet looks unexpectedly unscored or scored differently from a previous fill, ask the pharmacist whether the pharmacy changed suppliers before making assumptions about the contents.
An NDC identifies a drug-listing or package presentation; an ANDA is an FDA application pathway used for approved generics. These records answer different questions. An NDC alone is not an approval certificate, and neither an approved application nor a listed package proves current pharmacy stock. The Orange Book provides approval and applicable therapeutic-equivalence information, while labeling records describe particular products and packaging.
The company named on a package may be a labeler, distributor, relabeler or repackager rather than the original manufacturer. For example, the Preferred Pharmaceuticals and Proficient Rx package identifiers in the table are associated with tablets originating from other source products. Different NDCs can therefore describe different package channels without necessarily indicating different tablet formulations.
The source-product and repackager fields can be especially relevant when a consumer searches an NDC from a carton but receives a different identifier on the dispensing label. Those numbers may refer to different levels of the same supply chain. The pharmacist can reconcile them using actual dispensing records; an online NDC lookup alone cannot verify the contents of the patient container.
A 14-count or 20-count package describes a published distribution configuration, not the number of tablets a patient should receive. Pharmacies may dispense an authorized quantity from a stock bottle into a patient-labeled container. Compare the prescribed quantity and actual dispensed product rather than treating a manufacturer package photograph as an individualized order.
For broader company and source-product relationships, see the generic manufacturer and labeler guide. This page uses those distinctions only to help identify an 875 mg tablet and interpret its package record.
Start with the valid prescription. Confirm that it specifies plain amoxicillin tablets, 875 mg per unit, and check the authorized quantity and prescriber directions. If a search result omits the full drug name or dosage form, ask the pharmacy to identify the intended finished product rather than choosing an item from the result list.
Next, ask the pharmacist to confirm the actual product selected: its manufacturer or labeler, imprint, dosage form and any relevant difference from an earlier fill. At pickup or delivery, compare the patient name, medicine, 875 mg strength, tablet form, quantity and directions on the pharmacy-generated label with the prescription. An unexplained mismatch should be resolved before taking the medicine.
If the listed NDC is unavailable, another appropriately approved product may be considered only through the pharmacy’s lawful dispensing and substitution process. A missing package does not necessarily mean every plain-amoxicillin 875 mg tablet is unavailable. A proposal to supply amoxicillin/clavulanate is different because it adds an active ingredient and requires professional prescription review.
A change in tablet appearance is a separate question from whether the prescription is ready. A new supplier may produce a different imprint even when the strength and form remain unchanged, while a pharmacy may show a product listing that has not yet been allocated to an individual prescription. Asking the pharmacist to identify the actual tablet and confirm readiness resolves those two uncertainties without assuming an unauthorized substitution.
Finally, distinguish a searchable product listing from confirmed stock and a completed prescription. An online catalog may show a tablet before the pharmacy has reviewed the prescription, obtained inventory or marked the order ready. The local amoxicillin pharmacy guide covers pickup and readiness questions.
Raise unexpected tablet appearance, damaged packaging, ingredient concerns or a history of serious penicillin-class reactions with the pharmacist or prescriber. Do not use leftover antibiotics, substitute medicines or alter a prescribed course to bridge a supply problem.
Compare quotations only when they refer to plain amoxicillin 875 mg tablets and the same prescribed quantity. Confirm whether the amount is a cash price, insurance cost sharing or a discount-card quote, and whether fees are included. A product’s imprint, labeler or original stock-bottle count does not determine the patient’s final price.
A price shown for a 14-count repackaged bottle may not be comparable with an estimate for a different prescribed count. Similarly, a discount-card search result can reflect a different participating pharmacy or different payment conditions than the patient’s insurance claim. Ask for the final transaction basis rather than ranking raw search snippets.
Use the amount payable for the authorized prescription quantity, not a manufacturer bottle price. Costs for a separate consultation or clinical visit should not be silently included in the tablet price. The amoxicillin pricing guide covers broader cost comparisons; a preliminary offer still does not guarantee that the pharmacy can fill the prescription.
No. Plain amoxicillin 875 mg is a single-ingredient product, whereas amoxicillin/clavulanate 875/125 mg contains two active ingredients. The shared 875 mg number does not make the products interchangeable. The pharmacist should confirm which medicine the clinician prescribed before a prescription is filled.
The conventional U.S. product records discussed here describe 875 mg amoxicillin as a film-coated tablet. Common conventional amoxicillin capsule labels describe 250 mg and 500 mg strengths. A listing that says only “amoxicillin 875” should therefore be checked for the precise drug name and dosage form rather than interpreted from the number alone.
Different finished products may have different coatings, shapes and imprints. For example, published U.S. labels include a white-to-yellowish GG-962 tablet and pink A/6|7 or AMOXIL-imprinted tablets. Appearance alone is not a sufficient authenticity check; ask the pharmacy to reconcile the imprint with its product record.
No. GG-962 is associated with a particular documented 875 mg tablet family. Other 875 mg products have different imprints, and repackaged items can use different package NDCs even where the underlying tablet originates from the same source. Confirm the actual dispensed product through the pharmacy.
A score line is not personalized permission to split or modify a tablet. Whether a specific tablet can be divided appropriately, and whether doing so makes sense for an individual prescription, must be checked with the pharmacist or prescriber. Do not change the prescribed strength or instructions based on appearance.
No. An NDC is a product or package identifier, not an FDA-approval certificate or real-time inventory feed. Approval and therapeutic-equivalence information require a separate regulatory check. Even a correctly listed product can be unavailable at a particular pharmacy or not currently sold in that package.
Not necessarily, but the pharmacy must determine what the prescription permits and comply with applicable substitution and dispensing rules. Ask the pharmacist to explain the product selected and resolve any concerns about appearance or ingredients. Do not make the substitution decision based on a search result.
No. A labeled 20-count bottle describes a packaging presentation, not an individualized prescribed quantity. The pharmacy may dispense a different authorized quantity into a patient-labeled container. The quantity and directions on that label should match the prescription, and discrepancies should be clarified before use.
Compare the same plain-amoxicillin tablet strength, prescribed quantity and channel-specific final cost. Cash quotes, insurance copays and discount-card prices may differ and should not be treated as combinable without checking the terms. A quoted amount is not a guarantee that the pharmacy can dispense the prescribed product.